Vimnerixin

Cat. No.: HY-145640

CAS No.: 1418112-77-2

Molecular Formula: $C_{19}H_{25}FN_4O_5S_2$

Molecular Weight: 472.55

Target: CXCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (211.62 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.1162 mL	10.5809 mL	21.1618 mL
5 mM	0.4232 mL	2.1162 mL	4.2324 mL
10 mM	0.2116 mL	1.0581 mL	2.1162 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease[1].

IC_{50} & Target

CXCR2[1]

In Vivo

Assessment of Pharmacokinetics (PK) profile of Vimnerixin in rat and dog[1]

.

In Vivo PK	Rat	Dog
Predicted hepatic metabolic CL (ml/min per kilogram)	1.7	0.80

Observed CL (ml/min per kilogram)	2.4	0.50
CL_{renal} (mL/min per kilogram)	<0.01	<0.01
$CL_{biliary}$ (mL/min per kilogram)	<0.01	0.04
In vivo/in vitro unbound CL_{int}[c]	1.4	0.6
V_{SS} (l/kg)	0.19	0.15
$T_{1/2}$ (h) (PO)	1.3	3.7
	(2.7)	(8.4)
F (%)	45	82

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Gardiner P, et al. Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metab Dispos. 2019;47(8):865-873.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA